Editing Trials (Cancer Center of Kuopio University Hospital)

{{forpatients}}
{{forproviders}}
{{forresearchers}}
Go back to [[Cancer Center of Kuopio University Hospital]] page

'''NCTID''': NCT04597125
 '''Title''': Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH
 '''Study Summary''': Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participants with prostate gland cancer which has spread to the bone and progressed on or after one line of NAH therapy. Meanwhile researchers want to compare the safety of radium-223 dichloride and NAH therapy. Radium-223 dichloride is known as a radioactive drug that is taken up by bones after it is injected into the body. It works by giving off a type of radioactivity that travels a very short distance and kills the tumor cells that have spread to the bone without major effects to the healthy cells. It has been approved in many countries for the treatment of patients with prostate cancer which has spread to the bone. The NAH drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced prostate cancer.  Participants in this study will receive either Radium-223 dichloride or a NAH therapy. Radium-223 dichloride will be given as an infusion into one of the veins on Day 1 of each 4-week cycle for a total of up to 6 cycles. Oral NAH therapy will be given per the standard approved dose once daily until the disease has progressed. Participants will visit the hospital or clinic every 2 weeks for the first 6 cycles, and only on the first day of each cycle from cycle 7 and onwards. Observation for each participant will last for about 2 years in total. Blood and urine samples will be collected from the participants and participants will be asked to complete questionnaires about the well-being and the pain.
 '''Sponsor''': Bayer
 '''Intervention''': Radium-223 dichloride (Xofigo, BAY88-8223)
 '''Start Date''': 2020-11-09
 '''Last Updated''': 2023-11-14
 '''Number of Patients''': 696
 '''Recruitment Status''': RECRUITING
 '''Condition''': Metastatic Castrate Resistant Prostate Cancer (mCRPC)
'''NCTID''': NCT04680052
 '''Title''': A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
 '''Study Summary''': This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.
 '''Sponsor''': Incyte Corporation
 '''Intervention''': tafasitamab
 '''Start Date''': 2021-04-15
 '''Last Updated''': 2023-08-18
 '''Number of Patients''': 654
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': Follicular Lymphoma
'''NCTID''': NCT04736706
 '''Title''': A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
 '''Study Summary''': The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).  The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
 '''Sponsor''': Merck Sharp & Dohme LLC
 '''Intervention''': Pembrolizumab
 '''Start Date''': 2021-04-14
 '''Last Updated''': 2023-11-24
 '''Number of Patients''': 1653
 '''Recruitment Status''': RECRUITING
 '''Condition''': Carcinoma, Renal Cell
'''NCTID''': NCT00003991
 '''Title''': Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
 '''Study Summary''': RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission.  PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy.
 '''Sponsor''': Maxim Pharmaceuticals
 '''Intervention''': aldesleukin
 '''Start Date''': 1998-07
 '''Last Updated''': 2013-11-06
 '''Number of Patients''': 360
 '''Recruitment Status''': COMPLETED
 '''Condition''': Leukemia
'''NCTID''': NCT00646854
 '''Title''': Alemtuzumab and CHOP in T-cell Lymphoma
 '''Study Summary''': The purpose of this study is to determine efficacy and safety of the monoclonal antibody MabCampath® (alemtuzumab) combined with chemotherapy in the treatment of T-cell lymphoma.
 '''Sponsor''': Aarhus University Hospital
 '''Intervention''': CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab
 '''Start Date''': 2008-06
 '''Last Updated''': 2019-03-01
 '''Number of Patients''': 136
 '''Recruitment Status''': COMPLETED
 '''Condition''': Lymphoma, T-Cell, Peripheral
'''NCTID''': NCT04195750
 '''Title''': A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
 '''Study Summary''': The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
 '''Sponsor''': Merck Sharp & Dohme LLC
 '''Intervention''': Belzutifan
 '''Start Date''': 2020-02-27
 '''Last Updated''': 2022-08-01
 '''Number of Patients''': 736
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': Carcinoma, Renal Cell
'''NCTID''': NCT05429268
 '''Title''': Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
 '''Study Summary''': The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
 '''Sponsor''': Incyte Corporation
 '''Intervention''': Tafasitamab
 '''Start Date''': 2022-12-23
 '''Last Updated''': 2023-11-24
 '''Number of Patients''': 81
 '''Recruitment Status''': RECRUITING
 '''Condition''': Large B-Cell Lymphoma
'''NCTID''': NCT03625037
 '''Title''': First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
 '''Study Summary''': The trial is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). The trial consists of 3 parts:  * a dose-escalation part (Phase 1, first-in-human (FIH)) * an expansion part (Phase 2a) * a dose-optimization part (Phase 2a)
 '''Sponsor''': Genmab
 '''Intervention''': Epcoritamab
 '''Start Date''': 2018-06-26
 '''Last Updated''': 2023-08-08
 '''Number of Patients''': 786
 '''Recruitment Status''': RECRUITING
 '''Condition''': Diffuse Large B-cell Lymphoma (DLBCL)
'''NCTID''': NCT03155997
 '''Title''': Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
 '''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.
 '''Sponsor''': Eli Lilly and Company
 '''Intervention''': Abemaciclib
 '''Start Date''': 2017-07-12
 '''Last Updated''': 2023-07-14
 '''Number of Patients''': 5637
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': Breast Cancer
'''NCTID''': NCT03395197
 '''Title''': Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
 '''Study Summary''': This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
 '''Sponsor''': Pfizer
 '''Intervention''': Talazoparib with enzalutamide
 '''Start Date''': 2017-12-18
 '''Last Updated''': 2023-08-02
 '''Number of Patients''': 1125
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': mCRPC
'''NCTID''': NCT04821622
 '''Title''': Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
 '''Study Summary''': The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.
 '''Sponsor''': Pfizer
 '''Intervention''': talazoparib plus enzalutamide
 '''Start Date''': 2021-05-12
 '''Last Updated''': 2023-11-22
 '''Number of Patients''': 599
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': Prostate Cancer
'''NCTID''': NCT04332822
 '''Title''': A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
 '''Study Summary''': This is a phase III, randomized, open-label, multicenter trial, conducted in Sweden, Norway, Finland, Denmark, Italy and Switzerland, in elderly patients with untreated diffuse large B-cell lymphoma. Elderly is defined as either ≥80 years of age, or ≥75 years and frail, according to a simplified Comprehensive Geriatric Assessment. Patients will be randomized 1:1 to either the standard treatment for this population, R-miniCHOP, or an experimental regimen, R-pola-miniCHP, where vincristine is substituted by an immunoconjugate, polatuzumab vedotin. The duration of the screening period is up to 4 weeks. The duration of active treatment is 18 weeks in both arms, and patients will be followed up to 36 months after end of treatment. Start of enrollment is planned in Q1 2020, and the last visit of the last patient included (end of trial) is estimated in Q1 2026.
 '''Sponsor''': Nordic Lymphoma Group
 '''Intervention''': R-pola-mini-CHP
 '''Start Date''': 2020-08-19
 '''Last Updated''': 2021-07-09
 '''Number of Patients''': 200
 '''Recruitment Status''': RECRUITING
 '''Condition''': DLBCL
'''NCTID''': NCT05214183
 '''Title''': Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
 '''Study Summary''': This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL).  Acalabrutinib (ACP-196) is a next generation bruton tyrosine kinase (BTK) inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab.  In this trial proposal, we will also assess the activity of this combination in comparison to a historical control of ibrutinib + rituximab, consisting of the experimental arm of ibrutinib + rituximab in the randomized ENRICH trial (EudraCT number 2015-000832-13), and data from our previous trial with R-bendamustine-lenalidomide (NLG-MCL4).  The duration of treatment will be a minimum of 12 months. Patients in molecular remission in blood and bone marrow and in complete remission according to CT, will then stop acalabrutinib, but continue on rituximab for a maximum of 36 months. Patients that are minimal residual disease positive (MRD+) will be evaluated again every 6 months and continue on acalabrutinib for a maximum of 36 months.  Patients without a molecular marker, that cannot be followed with MRD, will stop treatment if in CR with PET at 12 months, and be followed by PET-CT every 6 months for a maximum of 36 months.  Patients who convert back to MRD positive after stopping acalabrutinib are reinstalled on acalabrutinib until progression.  Patients with TP53 aberrations and/or blastoid histology, will monitor MRD but continue with treatment until progression regardless of MRD results.  A planned interim analysis will be performed when 40 patients have undergone response assessment after 6 months, for futility and efficacy.  If less than 16 of 40 patients obtain a CR, the trial will be stopped due to futility.
 '''Sponsor''': Nordic Lymphoma Group
 '''Intervention''': Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
 '''Start Date''': 2021-12-15
 '''Last Updated''': 2022-02-14
 '''Number of Patients''': 80
 '''Recruitment Status''': RECRUITING
 '''Condition''': MCL
'''NCTID''': NCT01905943
 '''Title''': A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
 '''Study Summary''': This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's discretion. Each participant will be followed until 30 months after the last participant has been enrolled. Total length of the study is anticipated to be approximately 5 years.
 '''Sponsor''': Hoffmann-La Roche
 '''Intervention''': Bendamustine
 '''Start Date''': 2013-11-04
 '''Last Updated''': 2019-10-28
 '''Number of Patients''': 979
 '''Recruitment Status''': COMPLETED
 '''Condition''': Chronic Lymphocytic Leukemia
'''NCTID''': NCT05132582
 '''Title''': A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
 '''Study Summary''': This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease.  Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).  In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in.  All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.
 '''Sponsor''': Seagen Inc.
 '''Intervention''': Tucatinib
 '''Start Date''': 2022-03-07
 '''Last Updated''': 2023-11-21
 '''Number of Patients''': 650
 '''Recruitment Status''': RECRUITING
 '''Condition''': HER2 Positive Breast Cancer
'''NCTID''': NCT02730416
 '''Title''': Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
 '''Study Summary''': This study will evaluate the role of addition of an anti-angiogenic agent (Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance treatment in primary advanced or with first relapse of endometrial cancer.
 '''Sponsor''': Nordic Society of Gynaecological Oncology - Clinical Trials Unit
 '''Intervention''': Nintedanib or Placebo; Carboplatin, Paclitaxel
 '''Start Date''': 2016-12-12
 '''Last Updated''': 2023-09-21
 '''Number of Patients''': 146
 '''Recruitment Status''': COMPLETED
 '''Condition''': Endometrial Cancer
'''NCTID''': NCT05159245
 '''Title''': The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
 '''Study Summary''': This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.
 '''Sponsor''': Helsinki University Central Hospital
 '''Intervention''': Alectinib
 '''Start Date''': 2021-12-10
 '''Last Updated''': 2023-09-22
 '''Number of Patients''': 250
 '''Recruitment Status''': RECRUITING
 '''Condition''': Advanced Cancer
'''NCTID''': NCT03038100
 '''Title''': A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
 '''Study Summary''': This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.
 '''Sponsor''': Hoffmann-La Roche
 '''Intervention''': Paclitaxel
 '''Start Date''': 2017-03-08
 '''Last Updated''': 2023-02-17
 '''Number of Patients''': 1301
 '''Recruitment Status''': COMPLETED
 '''Condition''': Ovarian Cancer
'''NCTID''': NCT00989131
 '''Title''': Study of Paclitaxel in Patients With Ovarian Cancer
 '''Study Summary''': RATIONALE: Paclitaxel is one of the most widely used human anticancer agents. Paclitaxel has a low degree of solubility and Cremophor EL is typically used as the solubiliser. Cremophor EL is known to cause hypersensitivity reactions that can be life-threatening. As Paclical® does not contain Cremophor EL, hypersensitivity reactions can be expected to be less.  PURPOSE: To study the efficay and safety of two different formulations of paclitaxel, Paclical® and Taxol®.
 '''Sponsor''': Oasmia Pharmaceutical AB
 '''Intervention''': Paclical®
 '''Start Date''': 2009-02
 '''Last Updated''': 2014-02-04
 '''Number of Patients''': 789
 '''Recruitment Status''': COMPLETED
 '''Condition''': Epithelial Ovarian Cancer
'''NCTID''': NCT01379989
 '''Title''': INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
 '''Study Summary''': The objective of this multicentric, randomised, Phase III study is to demonstrate superiority, in terms of survival, of trabectedin and Pegylated Liposomal Doxorubicin (PLD) versus carboplatin and PLD in partially-platinum sensitive ovarian cancer patients.
 '''Sponsor''': Mario Negri Institute for Pharmacological Research
 '''Intervention''': Carboplatin
 '''Start Date''': 2011-06
 '''Last Updated''': 2022-02-09
 '''Number of Patients''': 617
 '''Recruitment Status''': COMPLETED
 '''Condition''': Ovarian Cancer
'''NCTID''': NCT01367665
 '''Title''': STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
 '''Study Summary''': This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.
 '''Sponsor''': Hoffmann-La Roche
 '''Intervention''': vismodegib
 '''Start Date''': 2011-07-01
 '''Last Updated''': 2019-06-06
 '''Number of Patients''': 1232
 '''Recruitment Status''': COMPLETED
 '''Condition''': Basal Cell Carcinoma
'''NCTID''': NCT01524848
 '''Title''': Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
 '''Study Summary''': Patients with metastatic or locally advanced gastrointestinal stromal tumors (GIST) who develop resistance against the two hitherto approved drugs for this disease, the tyrosin kinase inhibitors (TKIs) imatinib and sunitinib, have a poor prognosis. Sometimes a further response may be achieved by other drugs, mainly other TKIs, which have been explored in different studies but not yet have been approved for clinical use. Pazopanib is a TKI inhibiting the tyrosin kinases KIT, PDGFRA, and VEGF 1-3, all of which have important roles in the pathogenesis of GIST. Theoretically, it may function in GIST, and it deserves investigational trials. The drug is approved for metastatic renal cancer and is relatively well tolerated. In this trial (SSG XXI), the disease control rate (DCR) = (CR+PR+SD) after 12 weeks of treatment will be assessed as the primary endpoint, and at the same time trough levels will be measured. Secondary endpoints include ORR, PFS, toxicity, and disease control rate in relation to trough level week 12 and in relation to the primary mutation of the tumor (if known). The goal is to include 72 patients in the trial, which is open and single arm.
 '''Sponsor''': Scandinavian Sarcoma Group
 '''Intervention''': Pazopanib
 '''Start Date''': 2012-02
 '''Last Updated''': 2017-05-10
 '''Number of Patients''': 72
 '''Recruitment Status''': COMPLETED
 '''Condition''': Gastrointestinal Stromal Tumors
'''NCTID''': NCT04663347
 '''Title''': Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
 '''Study Summary''': A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab (EPKINLY™) in combination with other standard of care (SOC) agents in participants with B-cell Non-Hodgkin Lymphoma (B-NHL).
 '''Sponsor''': Genmab
 '''Intervention''': rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
 '''Start Date''': 2020-11-03
 '''Last Updated''': 2023-08-08
 '''Number of Patients''': 662
 '''Recruitment Status''': RECRUITING
 '''Condition''': Diffuse Large B-Cell Lymphoma
'''NCTID''': NCT05173987
 '''Title''': Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
 '''Study Summary''': The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.  The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).
 '''Sponsor''': Merck Sharp & Dohme LLC
 '''Intervention''': pembrolizumab
 '''Start Date''': 2022-02-03
 '''Last Updated''': 2023-11-09
 '''Number of Patients''': 280
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': Endometrial Neoplasms
'''NCTID''': NCT01767155
 '''Title''': Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
 '''Study Summary''': Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.
 '''Sponsor''': AEterna Zentaris
 '''Intervention''': AEZS-108 / zoptarelin doxorubicin
 '''Start Date''': 2013-04
 '''Last Updated''': 2018-07-31
 '''Number of Patients''': 511
 '''Recruitment Status''': COMPLETED
 '''Condition''': Endometrial Cancer
'''NCTID''': NCT04961996
 '''Title''': A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
 '''Study Summary''': This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.  In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination with abemaciclib in a subset of the primary study population.
 '''Sponsor''': Hoffmann-La Roche
 '''Intervention''': Giredestrant
 '''Start Date''': 2021-08-27
 '''Last Updated''': 2023-11-18
 '''Number of Patients''': 4200
 '''Recruitment Status''': RECRUITING
 '''Condition''': Early Breast Cancer
'''NCTID''': NCT04221035
 '''Title''': High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
 '''Study Summary''': This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk neuroblastoma.
 '''Sponsor''': Gustave Roussy, Cancer Campus, Grand Paris
 '''Intervention''': Vincristine
 '''Start Date''': 2019-11-05
 '''Last Updated''': 2023-02-13
 '''Number of Patients''': 800
 '''Recruitment Status''': RECRUITING
 '''Condition''': High-Risk Neuroblastoma
'''NCTID''': NCT05587296
 '''Title''': A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
 '''Study Summary''': Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy.  VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these hormones from attaching to these receptors are currently used to slow or stop the growth of HR-positive breast cancer.  It is already known that women with HR-positive breast cancer benefit from this treatment. However, hot flashes are common medical problems related to this therapy. They negatively affect quality of life of many women and may lead to discontinuation (stopping) of this therapy.  The study treatment, elinzanetant is being developed to treat hot flushes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.  The main purpose of this study is to learn more about how well elinzanetant helps to treat hot flashes caused by anti-cancer therapy in women with or at high risk for developing HR-positive breast cancer compared to placebo. A placebo is a treatment that looks like a medicine but does not have any medicine in it.  To answer this, the doctors will ask the participants to record information about their hot flashes before treatment start and at certain time points during the treatment in an electronic diary. The researchers will then assess possible average changes in number and severity of hot flashes after 4 and 12 weeks of treatment.  To see how safe elinzanetant is compared to placebo. The study will collect information about the number of participants who have medical problems after taking treatment.  The study participants will be randomly (by chance) assigned to 2 treatment groups, A and B. The participants from treatment group A will take elinzanetant. The participants from treatment group B will start with placebo and then switch to elinzanetant.  All participants will continue taking the anti-cancer therapy they have been using when entering the study.  Dependent on the treatment group, the participants will either take elinzanetant or placebo as capsules by mouth once a day. After 12 weeks, the participants who have initially received placebo will switch to take elinzanetant for the remaining 40 weeks.  Each participant will be in the study for approximately 62 weeks. The treatment duration in the study will be 52 weeks. There will be up to 12 visits to the study site and 6 phone calls in between. Participants who completed the 52 weeks treatment phase, will be offered to continue treatment for another 2 years. Visit frequency: every 24 weeks until week 152.  During the study, the participants will:  * record information about their hot flashes * answer questions about their quality of life and other symptoms.  The doctors and their study team will:  * check the participants health and vital signs * take blood and urine samples * examine heart health using electrocardiogram (ECG) * examine pelvic organs like womb or ovaries using a trans vaginal ultrasound scan to see images of these organs * make images of the breast using x-ray (mammogram), a type of radiation that passes through the body to make images of the inside and/or by using ultrasound (if applicable) * check the health of the participant's cervix (neck of the womb) by taking a small sample of cells (smear test) for an analysis called cervical cytology (if applicable) * take an endometrial biopsy, a small piece of tissue from the lining of the womb (called the endometrium) for analysis. * ask the participants questions about what medicines they are taking and if they are having adverse events.  An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.  About 4 weeks after the participants take their last treatment, the study doctors and their team will check the participants' health.
 '''Sponsor''': Bayer
 '''Intervention''': Elinzanetant (BAY3427080)
 '''Start Date''': 2022-10-14
 '''Last Updated''': 2023-11-13
 '''Number of Patients''': 405
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
'''NCTID''': NCT05239728
 '''Title''': A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
 '''Study Summary''': The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy.  The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).
 '''Sponsor''': Merck Sharp & Dohme LLC
 '''Intervention''': Belzutifan
 '''Start Date''': 2022-03-15
 '''Last Updated''': 2023-11-18
 '''Number of Patients''': 1800
 '''Recruitment Status''': RECRUITING
 '''Condition''': Carcinoma, Renal Cell
'''NCTID''': NCT04697628
 '''Title''': Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
 '''Study Summary''': This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent).  Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.
 '''Sponsor''': Seagen Inc.
 '''Intervention''': tisotumab vedotin
 '''Start Date''': 2021-02-22
 '''Last Updated''': 2023-11-14
 '''Number of Patients''': 556
 '''Recruitment Status''': RECRUITING
 '''Condition''': Cervical Cancer
'''NCTID''': NCT05020236
 '''Title''': MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
 '''Study Summary''': The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received previous treatment including lenalidomide and a proteasome inhibitor will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will compare the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab compared to daratumumab, pomalidomide, and dexamethasone. Part 3 of the study will evaluate an alternative dosing schedule of elranatamab in combination with daratumumab. Participants in all parts of the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
 '''Sponsor''': Pfizer
 '''Intervention''': Elranatamab
 '''Start Date''': 2021-10-04
 '''Last Updated''': 2023-08-24
 '''Number of Patients''': 854
 '''Recruitment Status''': RECRUITING
 '''Condition''': Multiple Myeloma
'''NCTID''': NCT01317641
 '''Title''': Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
 '''Study Summary''': The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
 '''Sponsor''': Orion Corporation, Orion Pharma
 '''Intervention''': ODM-201
 '''Start Date''': 2011-03
 '''Last Updated''': 2017-03-29
 '''Number of Patients''': 136
 '''Recruitment Status''': COMPLETED
 '''Condition''': Prostate Cancer
'''NCTID''': NCT01429064
 '''Title''': Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
 '''Study Summary''': The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.
 '''Sponsor''': Orion Corporation, Orion Pharma
 '''Intervention''': ODM-201
 '''Start Date''': 2011-06
 '''Last Updated''': 2017-02-20
 '''Number of Patients''': 76
 '''Recruitment Status''': COMPLETED
 '''Condition''': Prostate Cancer
'''NCTID''': NCT04634877
 '''Title''': Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
 '''Study Summary''': The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
 '''Sponsor''': Merck Sharp & Dohme LLC
 '''Intervention''': Pembrolizumab
 '''Start Date''': 2021-01-10
 '''Last Updated''': 2023-11-21
 '''Number of Patients''': 990
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': Endometrial Neoplasms
'''NCTID''': NCT03522246
 '''Title''': A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
 '''Study Summary''': This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
 '''Sponsor''': pharmaand GmbH
 '''Intervention''': Rucaparib
 '''Start Date''': 2018-05-14
 '''Last Updated''': 2023-09-15
 '''Number of Patients''': 1000
 '''Recruitment Status''': ACTIVE_NOT_RECRUITING
 '''Condition''': Epithelial Ovarian Cancer
'''NCTID''': NCT01828489
 '''Title''': Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years
 '''Study Summary''': This study evaluates the effect of different induction courses in children and adolescents with newly diagnosed acute myeloid leukemia. In the first course patients are randomised to receive either standard anthracycline therapy with mitoxantrone or experimental DaunoXome. In the second course patients are randomised between standard treatment with ADxE (cytarabine, DaunoXome, etoposide) or experimental therapy with FLADx (fludarabine, cytarabine, DaunoXome).
 '''Sponsor''': Vastra Gotaland Region
 '''Intervention''': Randomisation course 1 mitoxantrone versus DaunoXome
 '''Start Date''': 2013-03
 '''Last Updated''': 2017-01-10
 '''Number of Patients''': 300
 '''Recruitment Status''': UNKNOWN
 '''Condition''': Pediatric Acute Myeloblastic Leukemia
'''NCTID''': NCT02477644
 '''Title''': Platine, Avastin and OLAparib in 1st Line
 '''Study Summary''': Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
 '''Sponsor''': Arcagy Research
 '''Intervention''': Olaparib
 '''Start Date''': 2015-05-06
 '''Last Updated''': 2022-08-02
 '''Number of Patients''': 806
 '''Recruitment Status''': COMPLETED
 '''Condition''': Ovarian Cancer
'''NCTID''': NCT04307576
 '''Title''': A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
 '''Study Summary''': ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.
 '''Sponsor''': Mats Heyman
 '''Intervention''': Omitted Doxorubicin
 '''Start Date''': 2020-07-13
 '''Last Updated''': 2023-11-21
 '''Number of Patients''': 6430
 '''Recruitment Status''': RECRUITING
 '''Condition''': Leukemia, Acute Lymphoblastic
'''NCTID''': NCT05428969
 '''Title''': A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB)
 '''Study Summary''': This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.
 '''Sponsor''': Faron Pharmaceuticals Ltd
 '''Intervention''': Bexmarilimab
 '''Start Date''': 2022-06-02
 '''Last Updated''': 2023-06-23
 '''Number of Patients''': 181
 '''Recruitment Status''': RECRUITING
 '''Condition''': Acute Myeloid Leukemia